Drug Discovery
This section features DDW articles on drug discovery and drug development.
Page 1 to 14 of 64 |     NEXT PAGE >
High-throughput spheroid culture By Hilary Sherman, Dr Richard M. Eglen & Audrey Bergeron Winter 2017/18
The cost of drug development is becoming unsustainable, partly due to the high attrition rate of drugs in clinical trials.

Read More

Breaking down silos in drug development - why interdisciplinary integration is fundamental for pharma's future By Dr Paul Overton Winter 2017/18
A silo mentality is an issue for any organisation, but it is particularly problematic for the pharmaceutical industry.

Read More

Discovery and development of inhaled biopharmaceuticals By Dr Simon Moore, Dr Kirsty Harper & Dr Sylwia Marshall Winter 2017/18
The impact and effective routes of non-clinical safety assessment of inhaled biopharmaceuticals.

Read More

Practicalities of conducting REPLICATION STUDIES in Preclinical Cancer Biology By Dr Nicole Perfito, Dr Rachel Tsui & Dr Elizabeth Iorns Winter 2017/18
The first results for the Reproducibility Project: Cancer Biology offer insights into the time and cost of conducting replication studies in preclinical cancer biology.

Read More

Drug Discovery in the Age of Big Data - The Impact of RNAi & CRISPR/Cas9 Technologies By Dr Prem Premsrirut Fall 2017
How RNA interference and CRISPR/Cas9 technologies are helping to build better mouse models and push drug discovery into a new era.

Read More

Nanomedicines - exploring the past, present and future By Professor Yvonne Perrie & Dr Euan Ramsay Fall 2017
Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class of vaccines.

Read More

How the B6 mouse strain is revolutionising drug discovery By Dr Philip Dube Fall 2017
Inbred mice are critical tools in biomedical research and one particular strain, known as C57BL/6 (Black 6 or B6, for short), is rapidly becoming the standard model for many applications and revolutionising modern research.

Read More

Advancing the drug discovery pipeline with early stage In vitro ADME and toxicity testing By Dr Maureen Bunger Summer 2017
With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its standard processes and procedures are as streamlined and effective as possible.

Read More

Raising the bar on the biologics potential Dr Michael Mouradian Summer 2017
In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment.

Read More

Pharma Derisking approaches to reduce liability to major metabolically-driven causes of drug attrition By Guy Webber Spring 2017
Intelligent application of early in vitro testing can help mitigate major drug development risks.

Read More

3D Cell Culture - A rapidly emerging technique for drug discovery By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen Spring 2017
The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures. Today, 3D cell cultures are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease.

Read More

A strategic vision for 21st Century drug discovery By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Winter 16/17
Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater understanding of the aetiology of diseases, it is generally accepted that the current approach to creating new small molecule therapeutics remains fundamentally inefficient.

Read More

Kinases and drug discovery: protein kinases as a validated drug target By Professor Said A. Goueli Winter 16/17
The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and pharmaceutical industries. The payoff for the pharmaceutical industries has been substantial.

Read More

Drug Discovery
Page 1 to 14 of 64 |     NEXT PAGE >